Exploring the potential of using verteporfin during hair transplants to minimize scarring and regenerate follicles, as well as discussing a possible standardized protocol for this treatment.
The conversation discusses the potential of GT20029 to stop hair loss and possibly regrow hair, considering the body's regenerative abilities. No specific treatments were mentioned due to the original post being removed.
Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.
Dutasteride significantly reduces DHT levels, potentially more effectively than finasteride, and is used to treat hair loss. Some users report side effects like reduced libido and mood changes, while others experience hair regrowth and increased testosterone.
AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.
A permanent hair loss solution could involve reprogramming hair follicles to resist DHT using mRNA and siRNA. However, high costs, safety concerns, and the pharmaceutical industry's preference for ongoing treatments over one-time cures are major obstacles, with finasteride and minoxidil remaining standard treatments.
HairClone is developing cell replacement treatments to rejuvenate and generate hair follicles, and has launched a crowdfunding campaign. A user expressed skepticism about the need for crowdfunding.
A new serum claims to enhance hair regrowth by amplifying oxygen delivery, improving the effectiveness of treatments like exosomes and peptides. Users are skeptical, questioning its efficacy compared to established treatments like Minoxidil and Finasteride.
Minoxidil and finasteride work through different mechanisms; minoxidil-dependent hair requires continued use to maintain growth, while finasteride prevents further hair loss but cannot sustain minoxidil gains alone. Current treatments like minoxidil, finasteride, and others need indefinite use, as no permanent solution exists yet.
PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.
PP405 is a potential hair loss treatment that may activate dormant hair follicles, but there are concerns about its effectiveness, cost, and side effects. Users discuss treatments like minoxidil, finasteride, and RU58841, expressing skepticism about PP405's long-term success and accessibility.
Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.
The conversation humorously discusses hair loss treatments, including Minoxidil, finasteride, RU58841, and topical 17 alpha estradiol, with some users joking about transitioning to female to avoid baldness. The overall tone is satirical, emphasizing self-acceptance and the lengths people might consider for hair restoration.
The conversation discusses making a topical melatonin solution for hair loss treatment, questioning if isopropyl alcohol can dissolve melatonin. Melatonin is soluble in lipids and alcohol, but it's unstable and should be mixed fresh regularly; it may help hair growth by affecting certain cellular signaling pathways and has anti-androgenic effects.
Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.
A 20-year-old experiencing hair shedding after starting oral finasteride is advised to continue treatment and consider adding topical minoxidil. Shedding is normal, and patience is needed for hair regrowth.
Androgenetic alopecia is caused by DHT affecting hair growth. Finasteride and minoxidil are used to manage hair loss by blocking DHT and promoting hair growth.
Verteporfin is being discussed for its potential to regrow hair and heal scars, possibly aiding hair transplants or replacing them. Some users are skeptical about its effectiveness, while others suggest combining it with microneedling for better results.
The user shared a 1-year progress on hair loss treatment using topical minoxidil twice daily, finasteride daily, microneedling, oral minoxidil, and Nizoral every three days, showing significant improvement. Commenters expressed admiration for the results and hope for their own hair recovery.
The potential of verteporfin to heal wounds without scarring; however, despite its promising preclinical trials and coverage from a major media outlet, there is still no official clinical trial result and the drug has only garnered attention from hair loss communities.
Concerns about a potential finasteride ban in the EU, possibly affecting the US, are discussed. Users doubt a ban, citing its widespread use and suggest alternatives like minoxidil and dutasteride.
Hairregeneration and follicle cloning are considered far from being feasible, with current treatments like finasteride, minoxidil, and hair transplants expected to remain dominant for the next 15-20 years. Some are hopeful that AI advancements might accelerate progress, but many remain skeptical about significant breakthroughs in the near future.
A new human trial using an FDA-approved treatment for wound healing called Verteporfin, which may potentially be able to reverse scarring and regrow hair in that area. The trial is only lasting one month so far.
Hair loss treatments like finasteride, minoxidil, and hair transplants have side effects and limitations. There is hope for future advancements in stem cell therapy and hair follicle regeneration, though skepticism about their effectiveness and timeline persists.
The conversation discusses the potential of Verteporfin for hairregeneration and improving hair transplant surgery to leave no scars. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
Treatments for hair loss, such as using AR receptor blockers and degraders, to see if follicles can regenerate in the long term. The conversation also discusses how hair transplants could be a potential solution.
A human trial of verteporfin, a drug that can inhibit wound healing by scarring and promote regeneration of original tissue and hair follicles to provide an unlimited source for hair transplants; people discussed the potential of this drug and how it could be rolled out in mainstream with more doctors getting on board.
Shiseido's S-DSC hairregenerative treatment in Japan focuses on improving existing hair by thickening miniaturized follicles, not creating new ones. There is limited patient feedback and long-term data available.
